Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results
Krystal Biotech announced a 24% year-over-year increase in global net product revenue for VYJUVEK, totaling $119.2 million in Q2 2026, with robust gross margins and expanding international launches. The company highlighted strong cash reserves of $1.1 billion, multiple ongoing and upcoming clinical trials across ophthalmology, respiratory, dermatol…